Multiple Myeloma Clinical Trial
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Summary
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
Full Description
This is a phase 3 multicenter, open-label, randomized study in participants with relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior therapies.
Participants receive the treatment determined by randomization for a maximum of approximately 5 years, up to 30 days prior to the final analysis data cutoff (DCO) date or until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or death (whichever occurs first). No crossover between the treatment arms is allowed.
This was an open-label study. However, the assessment of response and disease progression for the primary analysis was determined by an Independent Review Committee (IRC) in a blinded manner. Sensitivity analyses of response and disease progression were determined centrally by the sponsor using a validated computer algorithm (Onyx Response Computational Assessment [ORCA]) in a blinded manner.
Following progression or discontinuation of study drug(s), participants will have 1 follow-up visit (30 days [+3} after last dose of all study drug[s]). After disease progression, data on survival status and subsequent antimyeloma therapy will be gathered at long-term follow-up (LTFU) visits every 12 weeks (+/-2 weeks) until the Final Analysis DCO.
Eligibility Criteria
Inclusion Criteria:
Criteria 1 Relapsed or progressive multiple myeloma after last treatment
Criteria 2 Males or females ≥ 18 years of age
Criteria 3 Measurable disease with at least 1 of the following assessed within 21 days prior to randomization:
IgG multiple myeloma: serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL,
IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL,
urine M-protein ≥ 200 mg/24 hours,
in subjects without measurable serum or urine M- protein, serum free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio
Criteria 4 Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy
Criteria 5 Prior therapy with carfilzomib is allowed as long as the patient had at least a partial response (PR) to most recent therapy with carfilzomib, was not removed due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib, and will have at least a 6-month carfilzomib treatment-free interval from last dose received until first study treatment. (Patients may receive maintenance therapy with drugs that are not proteasome inhibitors or CD38 antibodies during this 6-month carfilzomib treatment free interval)
Criteria 6 Prior therapy with anti-CD38 antibodies is allowed as long as the patient had at least a PR to most recent therapy with CD38 antibody, was not removed due to toxicity, did not relapse within 60 days from intensive treatment (at least every other week) of CD38 antibody therapy, and will have at least a 6 month CD38 antibody treatment-free interval from last dose received until first study treatment
Other inclusion criteria may apply
Exclusion Criteria:
Criteria 1 Waldenström macroglobulinemia
Criteria 2 Multiple myeloma of IgM subtype
Criteria 3 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
Criteria 4 Plasma cell leukemia (> 2.0 * 10^9/L circulating plasma cells by standard differential)
Criteria 5 Myelodysplastic syndrome
Criteria 6 Known moderate or severe persistent asthma within the past 2 years
Criteria 7 Known chronic obstructive pulmonary disease (COPD) with a FEV1 < 50% of predicted normal
Criteria 8 Active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, screening ECG with corrected QT interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to randomization
Other exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 113 Locations for this study
Boca Raton Florida, 33486, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60637, United States
Fort Wayne Indiana, 46845, United States
Hattiesburg Mississippi, 39401, United States
Hackensack New Jersey, 07601, United States
New York New York, 10021, United States
Charlotte North Carolina, 28204, United States
Dover Ohio, 44622, United States
Charleston South Carolina, 29414, United States
Dallas Texas, 75246, United States
Liverpool New South Wales, 2170, Australia
St Leonards New South Wales, 2065, Australia
Westmead New South Wales, 2145, Australia
Herston Queensland, 4029, Australia
Woolloongabba Queensland, 4102, Australia
Adelaide South Australia, 5000, Australia
East Melbourne Victoria, 3002, Australia
Fitzroy, VIC Victoria, 3065, Australia
Geelong Victoria, 3220, Australia
Melbourne Victoria, 3004, Australia
Graz , 8036, Austria
Salzburg , 5020, Austria
Antwerpen , 2060, Belgium
Brussel , 1090, Belgium
Charleroi , 6000, Belgium
Gent , 9000, Belgium
Leuven , 3000, Belgium
Plovdiv , 4002, Bulgaria
Sofia , 1431, Bulgaria
Sofia , 1756, Bulgaria
Calgary Alberta, T2N 4, Canada
Edmonton Alberta, T6G 1, Canada
Ottawa Ontario, K1H 8, Canada
Toronto Ontario, M5G 2, Canada
Montreal Quebec, H1T 2, Canada
Brno , 625 0, Czechia
Hradec Kralove , 500 0, Czechia
Ostrava-Poruba , 708 5, Czechia
Plzen , 304 6, Czechia
Praha 2 , 128 0, Czechia
La Roche Sur Yon Cedex 9 , 85925, France
Le Chesnay cedex , 78157, France
Lille Cedex , 59037, France
Nantes Cedex 1 , 44093, France
Pessac Cedex , 33604, France
Pierre-Benite cedex , 69495, France
Poitiers Cedex , 86021, France
Vandoeuvre les Nancy Cedex , 54511, France
Athens , 10676, Greece
Athens , 11528, Greece
Patra , 26504, Greece
Thessaloniki , 54007, Greece
Bekescsaba , 5600, Hungary
Budapest , 1088, Hungary
Budapest , 1097, Hungary
Debrecen , 4032, Hungary
Szeged , 6725, Hungary
Nagoya-shi Aichi, 467-8, Japan
Toyohashi-shi Aichi, 441-8, Japan
Kamogawa-shi Chiba, 296-8, Japan
Fukuoka-shi Fukuoka, 811-1, Japan
Fukuoka-shi Fukuoka, 812-8, Japan
Ogaki-shi Gifu, 503-8, Japan
Maebashi-shi Gunma, 371-8, Japan
Shibukawa-shi Gunma, 377-0, Japan
Kyoto-shi Kyoto, 602-8, Japan
Niigata-shi Niigata, 951-8, Japan
Okayama-shi Okayama, 701-1, Japan
Suita-shi Osaka, 565-0, Japan
Kawagoe-shi Saitama, 350-8, Japan
Utsunomiya-shi Tochigi, 320-0, Japan
Tokushima-shi Tokushima, 770-8, Japan
Koto-ku Tokyo, 135-8, Japan
Shibuya-ku Tokyo, 150-8, Japan
Goyang-si, Gyeonggi-do , 10408, Korea, Republic of
Hwasun, Jeollanam-do , 58128, Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 03722, Korea, Republic of
Seoul , 05505, Korea, Republic of
Seoul , 06351, Korea, Republic of
Seoul , 06591, Korea, Republic of
Bialystok , 15-73, Poland
Chorzow , 41-50, Poland
Lublin , 20-09, Poland
Poznan , 60-56, Poland
Warszawa , 02-77, Poland
Wroclaw , 50-36, Poland
Brasov , 50015, Romania
Bucharest , 02232, Romania
Bucharest , 03017, Romania
Bucuresti , 02012, Romania
Bucuresti , 05009, Romania
Cluj-Napoca , 40012, Romania
Craiova , 20014, Romania
Nizhny Novgorod , 60312, Russian Federation
Petrozavodsk , 18501, Russian Federation
Samara , 44307, Russian Federation
Saratov , 41002, Russian Federation
Salamanca Castilla León, 37007, Spain
Badalona Cataluña, 08916, Spain
Barcelona Cataluña, 08036, Spain
Pamplona Navarra, 31008, Spain
Madrid , 28041, Spain
Taipei , 10002, Taiwan
Taipei , 11217, Taiwan
Ankara , 06100, Turkey
Ankara , 06590, Turkey
Izmir , 35040, Turkey
Samsun , 55139, Turkey
Leeds , LS9 7, United Kingdom
London , NW1 2, United Kingdom
Manchester , M20 4, United Kingdom
How clear is this clinincal trial information?